SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
Sepracor-Looks very promising
An SI Board Since August 1996
Posts SubjectMarks Bans Symbol
10280 115 0 SEPR
Emcee:  rkrw Type:  Unmoderated
Introduction Market Data Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
9205Congrads!kenhott-1/19/2006
9204Or from a pregnant wife! LOL JonRobohogs-1/19/2006
9203only a small portion of people with chronic sleep problems tells their doctor absammaster-1/19/2006
9202Merrill is at $135.5 and Lehman as at $140. Guidance was in mid $130s area. PiRobohogs-1/19/2006
9201Thanks Jon - much appreciate the data. How do your estimates for Q4 compare wiBiomaven-1/18/2006
9200Refill rate comparisons: <pre> L/A L/S L/Mkt CR/L (adj for launch week) Robohogs-1/17/2006
9199Refill rates for all primarily sleep drugs: <pre> Am CR AmTot Lun Roz SoRobohogs-1/17/2006
9198Lunesta Rx numbers: <pre> Total New Refill 4/1/2005 842Robohogs-1/17/2006
9197Mkt shares for entire launch of Lunesta - new share only. <pre> AmRRobohogs-1/17/2006
9196I have not seen actual data - my data sources are now drying up. But I did see Robohogs-1/17/2006
9195DELETEDRobohogs-1/17/2006
9194Pharmacist wages war on drug costs By Denise Gellene Los Angeles Times January Icebrg-1/15/2006
9193third and final call for any scrip data from the recent week. Should have been aIamarangerboy-1/13/2006
9192There is also an age range. Nebs for the very young and the very old, MDI's Biomaven-1/13/2006
9191MDI is a one shot deal. The Nebulizer treatment is usually for more severe attacIamarangerboy-1/12/2006
9190>>Nebu and mdi don't usually mix so there shouldn't be much switchIRWIN JAMES FRANKEL-1/12/2006
9189When you start feeding pigeons, you would have to expect more pigeons to show upkenhott-1/12/2006
9188Depends on how strong they think their case is. Patent case has nothing to do wirkrw-1/12/2006
9187would be surprised in Sepr does not take this all the way.... that franchise is Iamarangerboy-1/12/2006
9186That's MRK KG, not mrk US. The way these patent disputes go these days, itrkrw-1/12/2006
9185Levalbuterol patent challenge I seem to recall Peter and others discussing the Sidney Street-1/12/2006
9184One more plea for any information regarding last week's scrips.... would greIamarangerboy-1/12/2006
9183Perhaps AGN (not SEPR) is the poster child for unrealized leverage: investorshuDewDiligence_on_SI-1/11/2006
9182<i>Sepr has had a marketing infrastructure they haven't leveraged for DewDiligence_on_SI-1/11/2006
9181Maybe the problems allow us to more truly experience being there. We too can exA.J. Mullen-1/10/2006
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News